MACULAR BUCKLING FOR MYOPIA: A NOVEL APPROACH

The winner of the ASRS Winning Pitch Challenge proposed a new design that is easy to place for posterior pole retinal detachments.

BY LEVENT AKDUMAN, MD, FASRS; SERHAT ERMIS, MD; AND OZGUR ARTUNAY, MD

With the oncoming myopia pandemic and the aging population, we will be facing an exponential increase in the number of pathologic myopia patients with myopic traction maculopathy. As retina specialists, we need to be prepared for it with a solid understanding of the underlying pathophysiology and the available treatment options, including different types of macular buckles and emerging surgical techniques.

Currently, the FDA has not approved any macular buckles, but many have been used, with varying degrees of success, outside the United States for nearly 2 decades. Those include the Ando Plombe (Ondeko), T-shaped scleral buckle (FCI, Carl Zeiss Meditec), NPB macular buckle (AJL Ophthalmics), and adjustable MB (Micromed).

TRYING A NEW OPTION

We recently developed a titanium macular buckle, the Akduman Myopia Support Device (MSD) by LA Eye (Figure 1) and used it to repair a recurrent chronic macular hole in an eye with pathologic myopia. This buckle was awarded first place in the 2022 American Society of Retina Specialists’ (ASRS) Winning Pitch Challenge competition.

We placed this implant in a highly myopic eye that presented with a retinal detachment and maculoschisis (Video). At presentation, the patient was phakic with a moderate degree of cataract and a VA of hand motion in the right eye. The axial length of the eye was 28.77 mm, and the patient refracted to -11.25, -2.00 axis 72. Widefield imaging and OCT showed a staphyloma, a retinal detachment, and myopic maculoschisis (Figure 2).

Six months after placing the macular buckle without vitrectomy, the retina was attached and the maculoschisis was nearly resolved. The external indentation of the buckle alone had addressed the pathophysiology defined in the myopic traction maculopathy classification by Parolini et al. Six months after surgery, the patient’s VA was 20/100, even with the cataract (Figure 3). The axial length of the eye was reduced to 26.31 mm at the 6-month follow up, and the refraction improved to -4.00, -1.75 axis 55. Thus, 7.25 D of myopia was corrected at the same time with no change in astigmatic error. Subjectively, the patient expressed extreme satisfaction with his BCVA and the reduction of the refractive error.

THE DESIGN

There are several features and surgical maneuvers unique to this titanium implant, including the following:

- The supportive plate facing and indenting the macular area is concave, which naturally hugs the globe and supports the macula without changing its contour.
The stiffness and size of the buckle aim to provide a fixed final axial length after the surgery in all eyes, regardless of the initial axial length.

The large surface area covers the fovea with almost no risk of clinically significant decentering while placing it.

The material, size, and design allow for easy manipulation and surgical technique. Two-point fixation with 5/0 mersilene sutures, one at its body and one at the anterior inlet, fixate the titanium buckle with no chance of displacement. After placement, the anterior edge remains 8 mm to 10 mm from the limbus and is well covered with Tenon and conjunctiva.

One size fits all eyes, right or left.

Removal, if necessary, is easy given the buckle’s design and stiffness.

Unlike other macular buckles, this one has an inner concave surface and does not compress on the fovea, possibly avoiding long-term foveal changes. The natural contour of the device is designed to avoid any significant effect on the choroidal or retinal circulation secondary to the indentation.

**NEXT STEPS**

The Akduman MSD, with its unique design and simple surgical technique, may have a place in the retina specialist’s toolkit to manage several indications associated with myopia.

**TABLE. POTENTIAL INDICATIONS**

<table>
<thead>
<tr>
<th>Indication</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Myopic posterior pole retinal detachment</td>
<td>*FDA application in process, pending soon</td>
</tr>
<tr>
<td>Myopic maculoschisis</td>
<td><strong>Needs clinical studies for FDA application</strong></td>
</tr>
<tr>
<td>Myopic macular holes</td>
<td></td>
</tr>
<tr>
<td>Prevention/reduction of myopic maculopathy</td>
<td></td>
</tr>
<tr>
<td>• Maculoschisis</td>
<td></td>
</tr>
<tr>
<td>• Macular holes</td>
<td></td>
</tr>
<tr>
<td>• Choroidal neovascularization</td>
<td></td>
</tr>
<tr>
<td>• Myopic macular atrophy</td>
<td></td>
</tr>
<tr>
<td>• Progression of posterior staphyloma</td>
<td></td>
</tr>
<tr>
<td>Refraction reduction in myopia more than -12.00 D</td>
<td></td>
</tr>
</tbody>
</table>

Figure 2. The preoperative color photo of the posterior pole (A) and OCT scan (B) showed a staphyloma and myopic maculoschisis. Note the retinal detachment in the fovea.

Figure 3. Fundus imaging 6 months after the surgery showed the indentation in the macular area caused by the exoplant (A). No macular scarring or other adverse effects were seen at the 6-month follow-up. The indentation stayed well centered and stable. OCT imaging at 6 months demonstrated resolved subretinal fluid and nearly resolved maculoschisis (B).
pathologic myopia (Table). This device was voted as the best retinal innovation by a panel of four judges during the ASRS Winning Pitch Challenge competition in June 2022.

Disclaimers: The use of implants described in this article is not approved by the US FDA. The Akduman Myopia Support Device was developed and owned by Levent Akduman, MD, FASRS.


**LEVENT AKDUMAN, MD, FASRS**
- Adjunct Professor of Ophthalmology, Saint Louis University, EyeCare Partners and The Retina Center, St. Louis
- akduman@macularbuckle.com
- Financial disclosure: CEO/Founder (LA Eye, LLC); Speaker’s Bureau (Allergan/AbbVie); Owner (Akduman Myopia Support Device)

**OZGUR ARTUNAY, MD**
- Professor of Ophthalmology, University of Health Sciences, Department of Ophthalmology, Beyoğlu Eye Research Hospital, Istanbul, Turkey
- Financial disclosure: None

**SERHAT ERMIS, MD**
- Ophthalmologist, University of Health Sciences, Department of Ophthalmology, Başakşehir City Hospital, Istanbul, Turkey
- Financial disclosure: None